Department of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, California, United States of America.
Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, United States of America.
PLoS Genet. 2018 Nov 16;14(11):e1007755. doi: 10.1371/journal.pgen.1007755. eCollection 2018 Nov.
Recent genome-wide association studies (GWAS) have identified multiple new loci which appear to alter coronary artery disease (CAD) risk via arterial wall-specific mechanisms. One of the annotated genes encodes LMOD1 (Leiomodin 1), a member of the actin filament nucleator family that is highly enriched in smooth muscle-containing tissues such as the artery wall. However, it is still unknown whether LMOD1 is the causal gene at this locus and also how the associated variants alter LMOD1 expression/function and CAD risk. Using epigenomic profiling we recently identified a non-coding regulatory variant, rs34091558, which is in tight linkage disequilibrium (LD) with the lead CAD GWAS variant, rs2820315. Herein we demonstrate through expression quantitative trait loci (eQTL) and statistical fine-mapping in GTEx, STARNET, and human coronary artery smooth muscle cell (HCASMC) datasets, rs34091558 is the top regulatory variant for LMOD1 in vascular tissues. Position weight matrix (PWM) analyses identify the protective allele rs34091558-TA to form a conserved Forkhead box O3 (FOXO3) binding motif, which is disrupted by the risk allele rs34091558-A. FOXO3 chromatin immunoprecipitation and reporter assays show reduced FOXO3 binding and LMOD1 transcriptional activity by the risk allele, consistent with effects of FOXO3 downregulation on LMOD1. LMOD1 knockdown results in increased proliferation and migration and decreased cell contraction in HCASMC, and immunostaining in atherosclerotic lesions in the SMC lineage tracing reporter mouse support a key role for LMOD1 in maintaining the differentiated SMC phenotype. These results provide compelling functional evidence that genetic variation is associated with dysregulated LMOD1 expression/function in SMCs, together contributing to the heritable risk for CAD.
最近的全基因组关联研究(GWAS)已经确定了多个新的位点,这些位点似乎通过动脉壁特异性机制改变了冠心病(CAD)的风险。注释的基因之一编码 LMOD1(Leiomodin 1),它是肌动蛋白丝核蛋白家族的成员,在富含平滑肌的组织(如动脉壁)中高度富集。然而,尚不清楚 LMOD1 是否是该基因座的因果基因,以及相关变异如何改变 LMOD1 的表达/功能和 CAD 风险。使用表观基因组谱分析,我们最近确定了一个非编码调节变体 rs34091558,它与 CAD GWAS 变体 rs2820315 紧密连锁不平衡(LD)。在此,我们通过 GTEx、STARNET 和人冠状动脉平滑肌细胞(HCASMC)数据集的表达数量性状基因座(eQTL)和统计精细映射证明,rs34091558 是血管组织中 LMOD1 的顶级调节变体。位置权重矩阵(PWM)分析确定保护等位基因 rs34091558-TA 形成保守的叉头框 O3(FOXO3)结合基序,该基序被风险等位基因 rs34091558-A 破坏。FOXO3 染色质免疫沉淀和报告基因分析显示,风险等位基因 rs34091558-A 降低了 FOXO3 结合和 LMOD1 转录活性,这与 FOXO3 下调对 LMOD1 的影响一致。在 HCASMC 中,LMOD1 的敲低导致增殖和迁移增加,细胞收缩减少,而在 SMC 谱系追踪报告小鼠的动脉粥样硬化病变中的免疫染色支持 LMOD1 在维持分化的 SMC 表型中起关键作用。这些结果提供了令人信服的功能证据,表明遗传变异与 SMC 中 LMOD1 的表达/功能失调有关,共同导致 CAD 的遗传风险。